Real-world experience with obeticholic acid in patients with primary biliary cholangitis.

Author: , AlvaroDomenico, BaiocchiLeonardo, BelliaValentina, BertinoGaetano, BoldizzoniRoberto, CalvarusoVincenza, CannavòMaria, CarboneMarco, CasellaSilvia, CastellanetaAntonino, CazzagonNora, ChessaLuchino, ClaarErnesto, ColapietroFrancesca, CozzolongoRaffaele, CristoferiLaura, D'AmatoDaphne, D'AntòMaria, De GasperiElisabetta, De VincentisAntonio, DistefanoMarco, FagiuoliStefano, FelettiValentina, FloreaniAnnarosa, FontanaRosanna, FrazzettoEvelise, GalatiGiovanni, GerussiAlessio, GrassiGiuseppe, InvernizziPietro, IzziAntonio, LabancaSara, LleoAna, LositoFrancesco, MalinvernoFederica, MancusoClara, MarconiGiulia, MarzioniMarco, MorgandoAnna, MulinacciGiacomo, MuratoriLuigi, MussettoAlessandro, NiroGrazia Anna, O'DonnellSarah Elizabeth, OmazziBarbara, PalermoAndrea, PalittiValeria Pace, PellicanoRinaldo, PellicelliAdriano, PicardiAntonio, PicciottoAntonino, PigozziMarie Graciella, PoggiGuido, PompiliMaurizio, PonzianiFrancesca, PozzoniPietro, RoncaVincenzo, RosinaFloriano, RusselloMaurizio, SaccoRodolfo, ScifoGaetano, StoratoSilvia, TerreniNatalia, VanniEster, VenereRosanna, Vespasiani-GentilucciUmberto, ViganòMauro, VinciMaria

Paper Details 
Original Abstract of the Article :
BACKGROUND & AIMS: Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. METHODS: Patie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930359/

データ提供:米国国立医学図書館(NLM)

Obeticholic Acid: A Real-World Assessment for Primary Biliary Cholangitis

This research provides a real-world evaluation of [drug name] for treating [disease name], a chronic liver disease. The authors conducted a large-scale observational study to examine the effectiveness and safety of this drug in a diverse patient population. Their findings suggest that [drug name] can be effective in [percentage] of patients who do not respond well to standard treatment. However, the study also highlights [specific patient populations] who may experience more side effects.

Obeticholic Acid: A Promising Second-Line Treatment for Primary Biliary Cholangitis

The research indicates that [drug name] can be a valuable option for patients with [disease name] who have not responded adequately to standard treatment. However, it emphasizes the importance of careful monitoring for potential side effects and personalized treatment approaches.

Navigating the Complexities of Liver Disease: A Need for Personalized Treatment Strategies

This study underscores the importance of individualized care in managing [disease name]. Healthcare providers should carefully consider factors such as [specific patient characteristics] when choosing treatment options and monitoring for potential side effects.

Dr.Camel's Conclusion

This research, like a camel traversing the vast desert of liver disease, provides valuable insights into the real-world effectiveness of [drug name] in managing [disease name]. It highlights the need for personalized treatment approaches and careful monitoring to ensure optimal patient outcomes.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-04-21
Further Info :

Pubmed ID

33681748

DOI: Digital Object Identifier

PMC7930359

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.